Physicochemical and Functional Similarity Assessment Between Proposed Bevacizumab Biosimilar BAT1706 and Reference Bevacizumab

por Cao, Di, Deng, Chunping, Wang, Guangying, Mei, Xiong, Xie, Jianhua, Liu, Yuanmei, Liu, Yujie, Yang, Yili, Li, Shengfeng, Liu, Cuihua
Publicado 2023

BAT6026, a novel anti-OX40 antibody with enhanced antibody dependent cellular cytotoxicity effect for cancer immunotherapy

por Liang, Shizhong, Zheng, Dandan, Liu, Xiong, Mei, Xiong, Zhou, Congcong, Xiao, Cuizhen, Qin, Chao, Yue, Haitao, Lin, Jian, Liu, Cuihua, Li, Shengfeng, Yu, Jin-Chen
Publicado 2023

Safety, tolerability, and pharmacokinetics of BAT8001 in patients with HER2‐positive breast cancer: An open‐label, dose‐escalation, phase I study

por Hong, Ruoxi, Xia, Wen, Wang, Liye, Lee, Kaping, Lu, Qianyi, Jiang, Kuikui, Li, Shengfeng, Yu, Jinquan, Wei, Jin, Tang, Weijia, Zhou, Danyang, An, Xin, Huang, Jiajia, Xue, Cong, Bi, Xiwen, Shi, Yanxia, Yuan, Zhongyu, Xu, Fei, Wang, Shusen
Publicado 2021